Halobacterium salinarum, et pulveres in mole NMN AASraw facit?

TAK CDXXXVIII,

Rating: Category:

TAK438, also known as Vonoprazan Monocotyledones, quod novum medicina quia de acidum-related morbo in novo mechanism de actio dicitur kalium-competitive Acidum blockers (P-cabs) qui certatim deiciunt impediuntque binding de kalium ions ad H, K + -ATPase ( et nota quod protón sentinam) in ultima gradus in CARDIACUS secretio CARDIACUS acidum parietalis ergastulum: controls CARDIACUS acidum excremento. Acidum excremento fortis hoste inhibendi providet effectus.

depictio producti

basic proprietates

Product # TAK CDXXXVIII,
Number CAS 1260141, 27 2,
Molecular Formula C21H20FN3O6S
Pondus formulae 461.46
definition Vonoprazan Monocotyledones;
Tak-CDXXXVIII,
1260141, 27, 2;
Vonoprazan fumurate;
TAK438.
aspectus Alba ad off-album pulveris
Tractantem et repono Siccum, et in tenebris 0 - C pro brevis terminus IV (hebdomades dierum ad) -4 C non est diu terminum (in mensibus anni.)

 

Tak-CDXXXVIII Description

TAK438, also known as Vonoprazan Monocotyledones, quod novum medicina quia de acidum-related morbo in novo mechanism de actio dicitur kalium-competitive Acidum blockers (P-cabs) qui certatim deiciunt impediuntque binding de kalium ions ad H, K + -ATPase ( et nota quod protón sentinam) in ultima gradus in CARDIACUS secretio CARDIACUS acidum parietalis ergastulum: controls CARDIACUS acidum excremento. Acidum excremento fortis hoste inhibendi providet effectus.

In polita humanitate praediti CARDIACUS glandulis, Tak-curatio CDXXXVIII in cladem diutius et fortior Acidum formation pestis. Et praeceptum est effectus CDXXXVIII super Tak-cell parietalis CARDIACUS acidum excremento videbantur esse consociata cum physiologiam.

 

TAK CDXXXVIII, Mechanism de actio

Tak-CDXXXVIII (Vonoprazan fumarate) est pyrole secundario et kalium-competitive Acidum obstructore proscriptionum (P-CAB) qui certatim, caudices in kalium-binding site CARDIACUS C (+), K (+) - ATPase, clavis enzyme in processus de CARDIACUS acidum excremento. De compositis ac vi acidum potest thesaurus augendus ut providere in spatium longius recipit, inhibitionis de pkA 438 propter alkaline.

In polita humanitate praediti CARDIACUS glandulis, Tak-curatio CDXXXVIII in cladem diutius et fortior Acidum formation pestis. Et praeceptum est effectus CDXXXVIII super Tak-cell parietalis CARDIACUS acidum excremento videbantur esse consociata cum physiologiam.

 

Application TAK CDXXXVIII,

Tak-CDXXXVIII (Vonoprazan fumarate aut Vonoprazan) quod novum medicina quia de acidum-related morbo in novo mechanism de actio dicitur kalium-competitive Acidum blockers (P-cabs) qui certatim deiciunt impediuntque binding de kalium ions ad H, K + -ATPase (Phaseolus vulgaris et quae in sentinam) in ultima gradus in CARDIACUS secretio CARDIACUS acidum parietalis cellulis. Et probatus est pharmacum-related morbo in Japan, quia de acidum curatio est, inter CARDIACUS ulceris, duodenal ulceris, Bacillus subtilis subsp pylori in Adjunct et refluxus OESOPHAGITIS apud eradication of Bacillus subtilis subsp pylori GASTRITIS.

 

Monitum & CDXXXVIII Tak-Side Effectus

In communi latere effectus comprehendit:

▪ fluxus,

▪ nauseam et vomitum,

▪ constipation,

▪ dolor abdominis,

▪ cutis temere,

▪ eructationibus.

 

Hi omnes possibiles TAK438 parte effectus. Pro magis notitia, quaeritur vestri medicus et pharmacopola. Voca vestri medicus circa consilium medicinae ad latus effectus. Licet referre ad latus effectus FDA-1-800 FDA-MLXXXVIII.

 

Reference

[I] Arikawa ego, Nishida n, o Kurasawa, Hasuoka A, Hirase K, N Inatomi: Hori ego, Matsukawa J, Imanishi A, Kondo M, N Tarui, Hamada T, T Takagi, Yokota T, Kajino M. de Inventionis ad usum eorum pyrrole inde 1. [1. (II-fluorophenyl) -5 (pyridin-III-ylsulfonyl) -2H pyrrol-III-y-] N-e methylmethanamin fumarate (Tak-CDXXXVIII) ut a kalium-competitive acidum obstructore proscriptionum (P-CAB). Res J med. May MMXII X, LV (IX): 1-3. DOI: 1 / jm3t. Apr 438, PubMed Epub MMXII PMID: 2012.

[II] Kondo M, M Kawamoto, Hasuoka A, Kajino M, N Inatomi, Tarui N. High throughput protegendo de kalium-blockers competitive acidum. J 'collaborative text calcii acetas. Feb MMXII, XVII (II), 2-2012. DOI: 17 / 2. Sep 177, PubMed Epub MMXI PMID: 82.

[III] Shin, JM, Inatomi N, K Munson, Strugatsky D, E Tokhtaeva, Vagin Domine, Sachs G. Lactobacillus facti novam gustaverunt kalium-competitive in in CARDIACUS acidum obstructore proscriptionum H, K, faba, 3- [1 (5- fluorophenyl) -2 (pyridin-III-ylsulfonyl) -1H-III-y-pyrrol] N-e methylmethanamin monofumarate (Tak-CDXXXVIII). J Pharmacol Exp, patris. Nov MMXI, CCCXXXIX (II), 3-1. doi: 3 / jpet.438. Aug MMXI Epub PubMed PMID 2011: 339; NDLTD PMCID: PMC2.

[IV]: Hori ego, Matsukawa J, Yokota T, B Nishida, Kajino M, N. A studio Inatomi comparet Tak-de effectus antisecretory CDXXXVIII, novum competitive acidum, kalium obstructore proscriptionum, ex lansoprazole in animalibus. J Pharmacol Exp, patris. Iun MMXI, CCCXXXVII (III): 4-438. doi: 2011 / jpet.337. Mar 3, PubMed Epub MMXI PMID: 797.

[V] Matsukawa J: Hori ego, Nishida H, M Kajino, Inatomi studio N. A comparativo ad modum agendi ex Tak-CDXXXVIII, novum competitive acidum, kalium obstructore proscriptionum ac polita humanitate praediti lansoprazole in prima lepus CARDIACUS glandulis. Biol Pharmacol. I May MMXI, LXXXI (IX): 5-438. doi: 2011 / j.bcp.1. Mar Epub MMXI 81. PubMed PMID: 9.

[VI]: Hori U, A Imanishi, Matsukawa J, Tsukimi ego, Nishida II, Arikawa N, K Hirase, Kajino M, N. 6. Inatomi [1. (II-Fluorophenyl) -5 (pyridin-III-ylsulfonyl) -2H-III-y-pyrrol] N-e methylmethanamin monofumarate (Tak-CDXXXVIII), novum competitive acidum, kalium et efficax curatio de obstructore proscriptionum ad acidum-related morbo. J Pharmacol Exp, patris. Oct MMX, CCCXXXV (I): 1-3. doi: 1 / jpet.3. Iul 438 Epub MMX PubMed PMID: 2010.